Recombinant Human IGF-BP3重组人胰岛素样生长因子结合蛋白3

Accession

P17936

GeneID

3486

Source

E.coli-derived Human IGF-BP3 protein,Gly28-Lys291.

Molecular Weight

Approximately 28.8 kDa.

AA Sequence

GASSAGLGPV VRCEPCDARA LAQCAPPPAV CAELVREPGC GCCLTCALSE GQPCGIYTER CGSGLRCQPS PDEARPLQAL LDGRGLCVNA SAVSRLRAYL LPAPPAPGNA SESEEDRSAG SVESPSVSST HRVSDPKFHP LHSKIIIIKK GHAKDSQRYK VDYESQSTDT QNFSSESKRE TEYGPCRREM EDTLNHLKFL NVLSPRGVHI PNCDKKGFYK KKQCRPSKGR KRGFCWCVDK YGQPLPGYTT KGKEDVHCYS MQSK

Tag

None

Physical Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.

Purity

> 98 % by SDS-PAGE and HPLC analyses.

Biological Activity

Fully biologically active when compared to standard. The ED₅₀ as determined by inhibiting IGF-II induced proliferation of serum free human MCF-7 cells is less than 200 ng/mL, corresponding to a specific activity of > 5.0 × 10³ IU/mg in the presence of 15 ng/ml of rHuIGF-II.

Endotoxin

< 1.0 EU per 1μg of the protein by the LAL method.

Formulation

Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4.

Reconstitution

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.